

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

FITC anti-mouse CD45

RRID:AB_312973

Type: Antibody

Proper Citation

BioLegend Cat# 103108, RRID:AB_312973

Antibody Information

URL: http://antibodyregistry.org/AB_312973

Proper Citation: BioLegend Cat# 103108, RRID:AB_312973

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-mouse CD45

Description: This monoclonal targets CD45

Target Organism: mouse

Clone ID: Clone 30-F11

Antibody ID: AB_312973

Vendor: BioLegend

Catalog Number: 103108

Alternative Catalog Numbers: 103107

Record Creation Time: 20250820T031639+0000

Record Last Update: 20250820T154904+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-mouse CD45.

No alerts have been found for FITC anti-mouse CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 140 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pilat DJ, et al. (2026) The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease by impairing microglial function. *Neuron*, 114(1), 46.

Heaton AR, et al. (2026) Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors. *bioRxiv : the preprint server for biology*.

Verwaerde S, et al. (2026) Innate type 2 lymphocytes trigger an inflammatory switch in alveolar macrophages. *Immunity*, 59(1), 60.

Chen Z, et al. (2026) Fibroblast-derived alarmin promotes oral wound healing by activating regulatory T cells that relay pro-angiogenic and anti-inflammatory responses. *Cell reports*, 45(1), 116829.

Song X, et al. (2026) MHC-II-restricted neoantigen vaccine reverses immune microenvironment and overcomes resistance to immune-checkpoint inhibitors in cold tumors. *Med (New York, N.Y.)*, 7(1), 100936.

Benjamin JS, et al. (2025) 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation. *Cancer research communications*, 5(3), 476.

Liu W, et al. (2025) Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in stroke. *EBioMedicine*, 112, 105568.

Hu J, et al. (2025) CD169+ macrophages identify and eliminate tumor cells in colorectal cancer through CD169/CD43 interaction and FasL-driven apoptosis. *Cell reports*, 44(10), 116351.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. *Cell reports*, 44(11), 116526.

Lee W, et al. (2025) Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. *Cancer cell*, 43(1), 69.

Woo MS, et al. (2025) The immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosis. *Cell*, 188(17), 4567.

Guo C, et al. (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. *Cell reports. Medicine*, 6(10), 102399.

Peng X, et al. (2025) Virus envelope glycoprotein targeting bispecific T cell engager protects mice from lethal severe fever with thrombocytopenia virus infection. *Cell reports. Medicine*, 6(11), 102458.

Amuso VM, et al. (2025) Fibroblast-Mediated Macrophage Recruitment Supports Acute Wound Healing. *The Journal of investigative dermatology*, 145(7), 1781.

Tang WW, et al. (2025) A microRNA-regulated transcriptional state defines intratumoral CD8⁺ T cells that respond to immunotherapy. *Cell reports*, 44(2), 115301.

Tursi NJ, et al. (2025) Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity. *Cell reports. Medicine*, 6(4), 102035.

Guo J, et al. (2025) KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy. *Cancer cell*, 43(7), 1261.

Rozalén C, et al. (2025) TIM3⁺ breast cancer cells license immune evasion during micrometastasis outbreak. *Cancer cell*, 43(8), 1549.

Feng Y, et al. (2025) TBK1 phagosomal recruitment enhances antifungal immunity via positive feedback regulation with SRC. *Cell reports*, 44(7), 115972.

Kim DH, et al. (2025) Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis. *Cell reports. Medicine*, 6(4), 102047.